OpenAI has officially entered the neurotech sector by investing in Merge Labs, a startup co-founded by its CEO Sam Altman that aims to bridge the gap between human biology and artificial intelligence through non-invasive ultrasound technology. The venture recently secured $252 million in a funding round led by OpenAI, with participation from the private investment firm Bain Capital and Valve Corporation’s Gabe Newell, signaling a massive shift in the race for high-bandwidth brain-computer interfaces (BCIs).
Beyond Silicon: A $252 Million Bet on Hybrid Consciousness
The startup’s name, Merge Labs, draws direct inspiration from “the merge”—a Silicon Valley hypothesis where human cognition and machine intelligence fuse into a singular hybrid consciousness. Sam Altman, who previously backed Elon Musk’s Neuralink with a portion of its $1.3 billion capital, is now spearheading a distinct philosophical and technical path. Unlike its competitors, Merge envisions a future where interfaces are as accessible as consumer electronics, combining biology, hardware, and AI into a seamless form factor.
Ultrasound Over Implants: Redefining the BCI Race
While Neuralink and Synchron focus on invasive or semi-invasive physical hardware, Merge Labs is pioneering a “no-implant” strategy. The company utilizes deep-reaching ultrasound modalities to read and modulate neural activity indirectly by detecting changes in cerebral blood flow, rather than measuring electrical impulses via electrodes. “We’re developing entirely new technologies that connect with neurons using molecules instead of electrodes,” the company stated, emphasizing a design that avoids the risks associated with brain tissue surgery.
The Competitive Landscape: Merge vs. Neuralink and Synchron
The neurotech field is currently divided by methodology. Neuralink has already implanted devices in at least 12 volunteers, using electrodes that penetrate brain tissue. Synchron, which has raised $345 million, avoids direct tissue contact by placing its device within blood vessels. Merge Labs differentiates itself by remaining entirely external, aiming for a high-bandwidth connection that does not require a surgical suite, potentially lowering the barrier for widespread adoption.
Foundation Models for the Human Mind
OpenAI’s involvement extends beyond capital; the organization will collaborate with Merge Labs to build scientific foundation models. These AI systems are designed to interpret the “noisy” signals inherent in non-invasive neural monitoring. By training on vast datasets of brain activity, these models will allow the interface to adapt to individual users and interpret intent with high precision. This mirrors efforts by Synchron and Nvidia, who are similarly leveraging AI to transform raw neural data into intuitive digital actions.
From Nonprofit Roots to Commercial Scaling
Merge Labs originated as a spinoff from Forest Neurotech, a Los Angeles-based nonprofit research organization established in 2023. While Forest continues its mission to treat mental health disorders and brain injuries—currently conducting safety trials for a miniaturized ultrasound device in the UK—Merge serves as the commercial vehicle for scaling these innovations. The founding team brings together a high-caliber roster of researchers and entrepreneurs, including Mikhail Shapiro, Tyson Aflalo, Sumner Norman, Alex Blania, and Sandro Herbig.
